北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 核医学科  > 期刊论文
学科主题: 临床医学
题名:
Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway
作者: Han, Baiyu1,2; Cui, Hanzhi3; Kang, Lei4; Zhang, Xuelin5; Jin, Zhitao6; Lu, Lanmin1; Fan, Zhongyi1,2
关键词: Metformin ; Thyroid cancer ; mTOR ; Cell proliferation ; Cell migration ; EMT
刊名: TUMOR BIOLOGY
发表日期: 2015-08-01
DOI: 10.1007/s13277-015-3315-4
卷: 36, 期:8, 页:6295-6304
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: ACTIVATED PROTEIN-KINASE ; EPITHELIAL-MESENCHYMAL TRANSITION ; IN-VITRO ; TGF-BETA ; OVARIAN-CANCER ; BRAF MUTATION ; STEM-CELLS ; VIVO ; METASTASIS ; SUPPRESSES
英文摘要:

Mammalian target of rapamycin (mTOR) signaling pathways have been shown to be activated in thyroid cancer. Recent evidences have demonstrated that the antidiabetic agent metformin, an activator of 5′-AMP-activated protein kinase, can impair the proliferation and migration of cancer cells via inhibition of mTOR. However, the underlying mechanisms remain unclear. In this study, we show that metformin can inhibit mTOR pathway to impair growth and migration of the thyroid cancer cell lines. Cyclin D1 and c-Myc are important regulators of cancer cell growth, and we observed that treatment of thyroid cancer cells with metformin reduced c-Myc and cyclin D1 expression through suppression of mTOR and subsequent inhibition of P70S6K1 and 4E-BP1 phosphorylation. Metformin reduced epithelial to mesenchymal transition (EMT) in thyroid carcinoma cells. Moreover, metformin regulated expression of the EMT-related markers E-cadherin, N-cadherin, and Snail. Additionally, knockdown of TSC2, the upstream regulatory molecule of mTOR pathway, or treatment of rapamycin, the mTOR inhibitor, could abolish the effects of metformin to regulate thyroid cancer cell proliferation, migration, EMT, and mTOR pathway molecules. These results indicate that metformin can suppress the proliferation, migration, and EMT of thyroid cancer cell lines by inhibiting mTOR signaling. These findings suggest that metformin and its molecular targets may be useful in thyroid carcinoma therapy.

语种: 英语
WOS记录号: WOS:000360193800066
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51214
Appears in Collections:北京大学第一临床医学院_核医学科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.PLA, Hosp 309, Dept Oncol, Beijing, Peoples R China
2.Gen Hosp Second Artillery, Dept Cardiol, Beijing, Peoples R China
3.PLA, Hosp 264, Dept Endocrinol & Metab, Taiyuan 030000, Shanxi, Peoples R China
4.Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
5.Peking Univ, Hosp 1, Dept Nucl Med, Beijing 100871, Peoples R China
6.Peoples Liberat Army Gen Hosp, Dept Respirat, Beijing, Peoples R China

Recommended Citation:
Han, Baiyu,Cui, Hanzhi,Kang, Lei,et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway[J]. TUMOR BIOLOGY,2015,36(8):6295-6304.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Han, Baiyu]'s Articles
[Cui, Hanzhi]'s Articles
[Kang, Lei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Han, Baiyu]‘s Articles
[Cui, Hanzhi]‘s Articles
[Kang, Lei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace